Optimize Financial Inc Purchases Shares of 4,294 Illumina, Inc. $ILMN

Optimize Financial Inc acquired a new position in Illumina, Inc. (NASDAQ:ILMN) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 4,294 shares of the life sciences company’s stock, valued at approximately $408,000.

Several other institutional investors have also recently made changes to their positions in the business. Next Capital Management LLC bought a new position in Illumina in the 2nd quarter worth approximately $341,000. CWM LLC raised its position in shares of Illumina by 112.9% during the second quarter. CWM LLC now owns 76,711 shares of the life sciences company’s stock valued at $7,319,000 after buying an additional 40,676 shares during the last quarter. Generali Asset Management SPA SGR lifted its holdings in shares of Illumina by 51.6% in the third quarter. Generali Asset Management SPA SGR now owns 22,249 shares of the life sciences company’s stock worth $2,113,000 after buying an additional 7,574 shares in the last quarter. Andra AP fonden boosted its position in shares of Illumina by 426.3% during the second quarter. Andra AP fonden now owns 102,491 shares of the life sciences company’s stock worth $9,779,000 after acquiring an additional 83,017 shares during the last quarter. Finally, Aaron Wealth Advisors LLC grew its stake in Illumina by 342.6% during the third quarter. Aaron Wealth Advisors LLC now owns 10,476 shares of the life sciences company’s stock valued at $995,000 after acquiring an additional 8,109 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on ILMN shares. JPMorgan Chase & Co. lifted their price target on shares of Illumina from $105.00 to $130.00 and gave the company a “neutral” rating in a report on Monday, December 15th. Robert W. Baird set a $109.00 price objective on Illumina in a research report on Friday, October 31st. Weiss Ratings reiterated a “hold (c-)” rating on shares of Illumina in a research report on Monday, December 29th. Stifel Nicolaus increased their price target on Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a research note on Tuesday, January 20th. Finally, UBS Group lifted their price objective on Illumina from $110.00 to $120.00 and gave the stock a “neutral” rating in a research note on Friday, October 31st. Six research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Illumina presently has a consensus rating of “Hold” and an average price target of $127.18.

Insider Buying and Selling

In other Illumina news, insider Scott M. Davies sold 323 shares of the business’s stock in a transaction on Friday, December 12th. The shares were sold at an average price of $136.09, for a total transaction of $43,957.07. Following the transaction, the insider owned 17,887 shares in the company, valued at $2,434,241.83. The trade was a 1.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 2.60% of the stock is owned by insiders.

Illumina Trading Down 0.9%

Shares of NASDAQ ILMN opened at $134.19 on Thursday. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $155.53. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.12. The business’s 50 day moving average is $138.59 and its two-hundred day moving average is $115.87. The stock has a market capitalization of $20.50 billion, a P/E ratio of 30.09, a PEG ratio of 2.25 and a beta of 1.45.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.